Featured news from NHIVNA
HIV-related news from NAM
AbbVie pangenotypic combination cures 98% or above across genotypes
Keith Alcorn, 2016-11-16 15:20:00
AbbVie’s combination of glecaprevir and pibrentasvir cured
at least 98% of people with hepatitis C in three large clinical trials covering five out of six genotypes of the virus, and is likely to receive marketing approval in the
United States and European Union as the first ribavirin-free pangenotypic
direct-acting antiviral combination next year, the 2016 AASLD Liver Meeting heard
this week in Boston.
In another clinical trial the combination cured almost all genotype 3 patients who were treatment-experienced and/or had cirrhosis, the hardest groups of patients to cure of hepatitis C.
developing the combination of glecapravir (ABT-493) and pibrentasvir (ABT-530),
referred to as G/P by the company, as a pangenotypic regimen for hepatitis C
treatment. The combination is dosed once daily, without ribavirin.
is an HCV NS3/4A protease inhibitor active against all genotypes of hepatitis
C. Pibrentasvir is an NS5A inhibitor also active against all genotypes of hepatitis C virus (HCV).
Both agents are active against common variants that confer resistance to
first-generation agents of their classes. Glecaprevir is more potent against
genotype 3 than other HCV protease inhibitors, including products being
developed by Merck (grazoprevir) and Gilead (voxilaprevir)). Pibrentasvir has
demonstrated higher potency than most other NS5A inhibitors across all
This week results of three phase III studies of the
combination were presented at The Liver Meeting, including a comparison of 8-
and 12-week treatment regimens in people with genotype 1 infection. The studies
are code-named Endurance.